Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;4(2):122-8.
doi: 10.15420/aer.2015.04.02.122.

Developments in Cardiac Resynchronisation Therapy

Geoffrey F Lewis  1 , Michael R Gold  1
Affiliations

Developments in Cardiac Resynchronisation Therapy

Geoffrey F Lewis et al. Arrhythm Electrophysiol Rev. 2015 Aug.

Abstract

Cardiac resynchronisation therapy (CRT) is an important therapy for patients with heart failure with a reduced ejection fraction and interventricular conduction delay. Large trials have established the role of CRT in reducing heart failure hospitalisations and improving symptoms, left ventricular (LV) function and mortality. Guidelines from major medical societies are consistent in support of CRT for patients with New York Health Association (NYHA) class II, III and ambulatory class IV heart failure, reduced LV ejection fraction and QRS prolongation, particularly left bundle branch block. The current challenge facing practitioners is to maximise the rate of patients who respond to CRT and the magnitude of that response. Current areas of interest for achieving these goals include tailoring patient selection, individualising LV lead placement and application of new technologies and techniques for CRT delivery.

Keywords: Cardiac resynchronisation therapy; LV lead delivery; LV reverse remodelling; cardiac pacemaker; device programming; heart failure; implantable cardioverter/defibrillator; left bundle branch block; left ventricular function.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Models Showing Hazard Ratios and their 95 % Confidence Intervals for the Effects of Cardiac Resynchronisation Therapy vs Control
Figure 2:
Figure 2:. Endocardial Atrial Transseptal Approach
Figure 3:
Figure 3:. Changes in Left Ventricular End-systolic Volume, Left Ventricular End-diastolic Volume, Ejection Fraction and Quality of Life from Implant Baseline to 6 Months for the QLV Quartiles
See this image and copyright information in PMC

References

    1. Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation. 2013;128:2407–18. - PubMed
    1. Daubert JC, Saxon L, Adamson PB et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012;14:1236–86. - PubMed
    1. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–80. - PubMed
    1. Abraham WR, Fisher WG, Smith A et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53. - PubMed
    1. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50. - PubMed